The influence of variable-heavy chain families on IgG2, 3, 4, FcγRs and B-cell superantigens protein G and L binding using biolayer interferometry [0.03%]
采用生物层干涉测量技术研究可变重链基因型对IgG亚类、FcγRs和B细胞超抗原蛋白G和L的结合的影响
Anthony M Deacy,Samuel Ken-En Gan
Anthony M Deacy
As the most abundant immunoglobulin in blood and the most common human isotype used for therapeutic monoclonal antibodies, the engagement and activation of its Fc receptors by IgGs are crucial for antibody function. Assumed to be relatively...
Alpaca single B cell interrogation and heavy-chain-only antibody discovery on an optofluidic platform [0.03%]
基于光流片上细胞操控平台的羊驼单B淋巴细胞筛选与仅重链抗体发现技术
Mariya B Shapiro,Jacqueline Boucher,Anna Brousseau et al.
Mariya B Shapiro et al.
In vivo VHH discovery approaches have been limited by the lack of methodologies for camelid B cell interrogation. Here, we report a novel application of the Beacon® optofluidic platform to the discovery of heavy-chain-only antibodies by sc...
Correction: AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains [0.03%]
纠误：AB-Amy：借助机器学习预测治疗性单克隆抗体轻链淀粉样变风险
[This corrects the article DOI: 10.1093/abt/tbad007.]. © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. Al...
Published Erratum
Antibody therapeutics. 2023 May 26;6(3):180. DOI:10.1093/abt/tbad012 2023
Correction to: A mammalian cell display platform based on scFab transposition [0.03%]
Correction to: 培植基于scFab转座的哺乳动物细胞展示平台
[This corrects the article DOI: 10.1093/abt/tbad009.]. © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. Al...
Published Erratum
Antibody therapeutics. 2023 Jul 7;6(3):181. DOI:10.1093/abt/tbad015 2023
Jing Chang,Christoph Rader,Haiyong Peng
Jing Chang
In vitro display technologies have been successfully utilized for the discovery and evolution of monoclonal antibodies (mAbs) for diagnostic and therapeutic applications, with phage display and yeast display being the most commonly used pla...
AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains [0.03%]
AB-Amy：借助机器学习预测治疗性抗体轻链淀粉样变性风险
Yuwei Zhou,Ziru Huang,Yushu Gou et al.
Yuwei Zhou et al.
Over 120 FDA-approved antibody-based therapeutics are used to treat a variety of diseases.However, many candidates could fail because of unfavorable physicochemical properties. Light-chain amyloidosis is one form of aggregation that can lea...
Efficient production of bispecific antibodies-optimization of transfection strategy leads to high-level stable cell line generation of a Fabs-in-tandem immunoglobin [0.03%]
高效生产双特异性抗体-转染策略的优化可生成高效的串联Fab片段型免疫球蛋白稳定细胞系
Shiyong Gong,Chengbin Wu
Shiyong Gong
Bispecific antibodies (bsAbs) are often composed of more than two component chains, such as Fabs-in-tandem immunoglobin (FIT-Ig) comprising three different component chains, which bring challenges for generating a high proportion of the cor...
TransMHCII: a novel MHC-II binding prediction model built using a protein language model and an image classifier [0.03%]
TransMHCII：一种基于蛋白质语言模型和图像分类器的新型MHC-II结合预测模型
Xin Yu,Christopher Negron,Lili Huang et al.
Xin Yu et al.
The emergence of deep learning models such as AlphaFold2 has revolutionized the structure prediction of proteins. Nevertheless, much remains unexplored, especially on how we utilize structure models to predict biological properties. Herein,...
Characterization of HZ0412a, a novel potent humanized anti-IL-6 receptor antibody that blocks IL-6R binding to gp130 [0.03%]
一种新型强力人源化抗白细胞介素-6受体单克隆抗体HZ0412a的表征：能阻断白细胞介素-6受体与gp130结合
Jianzhong Han,Xiaolei Liu,Yue Xu et al.
Jianzhong Han et al.
Dysregulated elevation of interleukin-6 (IL-6) signaling is implicated in the pathogenesis of multiple pathophysiological states, and the functional neutralization of the IL-6 pathway with monoclonal antibodies has been proven an effective ...
Current status of drug development for patients with multiple myeloma: a review of comparison in China and the rest of world [0.03%]
中国与世界其他地区多发性骨髓瘤患者药物研发现状比较综述
Lei Huang,Jingyu Zhang,Elizabeth Punnoose et al.
Lei Huang et al.
Multiple myeloma (MM) is a highly heterogeneous malignancy. The treatment of MM has been significantly advanced in recent years. B cell maturation antigen (BCMA)-targeted immunotherapy and chimeric antigen receptor T (CAR-T) cell therapy ha...